Company news

Amarantus Bioscience Holdings, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Amarantus Announces Publication of Human Clinical Data for Engineered Skin Substitute in the Treatment of Life-Threatening Pediatric Severe Burns

August 8, 2016

Avant Diagnostics Presented Data on TheraLink® Pancreatic Cancer Assay at the International Symposium on Pancreas Cancer 2016

June 14, 2016

Amarantus Announces cGMP Manufacturing Readiness for Its Engineered Skin Substitute (ESS) Program at Lonza Walkersville

June 7, 2016

Amarantus Completes Sale of Diagnostics Division, Announces Fiscal Year 2015 and First Quarter 2016 Financial Results

June 3, 2016

OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference

May 31, 2016

Amarantus Announces Upcoming Investor Presentations

May 27, 2016

Avant Diagnostics Simultaneously Completes Acquisitions of Amarantus Diagnostics and Theranostics Health

May 12, 2016

Retired American Burn Association President Dr. David Ahrenholz to Present on Engineered Skin Substitute (ESS) at the Vatican's Third International Conference on the Progress of Regenerative Medicine and its Cultural Impact

April 25, 2016

Amarantus Announces Capital Infusion

April 21, 2016

Amarantus Announces Cancellation of Special Meeting of Shareholders

March 22, 2016

Avant Diagnostics, Amarantus Diagnostics and Theranostics Health Provide Updated Information for Conference Call to Discuss Business Combination

March 7, 2016

Avant Diagnostics and Amarantus Diagnostics to Combine Operations With Theranostics Health

March 7, 2016

Amarantus Diagnostics and Avant Diagnostics to Form 3-Way Business Combination with Theranostics Health

March 7, 2016

Amarantus Appoints Brian E. Harvey, MD PhD to Strategic Advisory Board

March 4, 2016

Amarantus Receives Notices of Allowance from European Patent Office for MANF and CDNF in the Treatment of Retinal Disorders

February 29, 2016

Amarantus and Lonza Walkersville, Inc. Provide Update on cGMP Manufacturing Readiness for the Engineered Skin Substitute (ESS) Program

February 22, 2016

Amarantus Announces $3M Capital Infusion

February 19, 2016

Amarantus Receives Orphan Drug Designation From the US FDA for Eltoprazine in the Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia

February 10, 2016

Amarantus to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference

February 9, 2016

Amarantus Requests Rare Pediatric Disease Designation from US FDA for MANF in the Treatment of Retinitis Pigmentosa

February 5, 2016

Amarantus Receives Dual Notices of Allowance from European Patent Office for Engineered Skin Substitute (ESS)

February 3, 2016

Amarantus Announces Issuance of Chinese Patent Covering Use of MANF for the Treatment of Parkinson's Disease

January 29, 2016

Amarantus Announces $1M Investment

January 27, 2016

Amarantus Enters Into Letter of Intent to Merge Diagnostics Business Unit Into Avant Diagnostics

January 19, 2016

Amarantus Enters into Letter of Intent to Merge Diagnostics Business Unit into Avant Diagnostics

January 19, 2016

Amarantus to Present at ICV Sonoma Event

January 15, 2016

Amarantus to Present at SeeThruEquity First Annual Microcap Healthcare Investor Conference

January 11, 2016

Amarantus Requests Rare Pediatric Disease and Orphan Drug Designations from US FDA for Engineered Skin Substitute in the Treatment of Giant Congenital Melanocytic Nevi

December 29, 2015

Amarantus Provides Update on cGMP Manufacturing Validation for the Engineered Skin Substitute (ESS) Program

December 22, 2015

Amarantus Announces Peer-Reviewed Publication Further Describing Mechanisms of Action for Eltoprazine in the Treatment of Parkinson's LID

December 16, 2015

Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Method of Treating Parkinson's Disease Levodopa-induced Dyskinesia (PD-LID)

December 15, 2015

StockNewsNow.com Publishes New SNNLive Video Interview with Amarantus BioScience Holdings, Inc.

December 14, 2015

Amarantus Retains WallachBeth Capital to Evaluate Strategic Options for MANF Gene Therapy Program

December 10, 2015

Amarantus Announces Positive Phase 2 Data for Eltoprazine in Alzheimer's Aggression

December 8, 2015

Amarantus to Present at ICV Manhattan Event on December 8, 2015

December 7, 2015

Amarantus to Present at LD Micro Main Event on December 3, 2015

December 3, 2015

Amarantus Selected by People's Bank of China for Anhui SME Cross-Border Investment and Trade Cooperation Conference

November 13, 2015

Amarantus Announces Issuance of Australian Patent No. 61/057,713 Covering Eltoprazine Treatment of Parkinson’s Disease and Alzheimer’s Disease

October 29, 2015

Amarantus Appoints Curtis Scribner, MD MBA as Sr. Vice President of Regulatory Affairs

October 26, 2015

Amarantus Submits Orphan Drug Designation Application to US FDA for Eltoprazine in the Treatment of Levodopa-Induced Dyskinesia

October 22, 2015

Amarantus to Present at BIO Investor Forum 2015

October 19, 2015

Past President of the American Burn Association Dr. David Ahrenholz Provides Video Interview on Potential of ESS for Treatment of Severe Burns

October 14, 2015

Amarantus Reports Preliminary 13-Year Longitudinal Follow-Up Human Patient Data for Engineered Skin Substitute Treatment of Congenital Giant Hairy Nevus

October 8, 2015

Amarantus Announces Publication of Study on Targeted Delivery of MANF to Brain Areas Associated With Parkinson's Disease

October 6, 2015

Amarantus to Present at the 2015 Aegis Growth Conference

October 5, 2015

Amarantus to Focus Near-Term Development Efforts on Engineered Skin Substitute for Indications in Rare Pediatric Diseases

October 1, 2015

Amarantus Closes $5.5 Million Capital Infusion Through the Issuance of a Combination of Preferred Stock and Secured Debt Convertible

October 1, 2015

Amarantus Announces an Interactive Live Webcast Presentation at VirtualInvestorConferences.com on October 1, 2015

September 30, 2015

OTC Markets Group to Host Virtual Investor Conference for OTCQX Life Science Companies - October 1

September 28, 2015

Amarantus Receives Orphan Drug Designation From the U.S. Food and Drug Administration for MANF for the Treatment of Retinal Artery Occlusion

September 14, 2015

← Newer news releases · Older news releases →

Decks

The 5 newest of 10 decks. Every deck is listed under its year.